Description of Conduct

On 17 September 2021, Medicines Australia (MA) lodged an application for re-authorisation (revocation and substitution) on behalf of itself and its members, the Generic and Biosimilar Medicines Association (GBMA) and its members, and other entities that have been or in the future will be notified by MA to the ACCC (the MA/GBMA Working Group). MA sought re-authorisation to enable MA/GBMA Working Group members to continue to implement a coordinated strategy in relation to the supply of essential medicines and related devices in response to the current COVID-19 pandemic (the Conduct).  

MA sought interim authorisation for the Conduct (as the previous authorisation was due to expire on 30 September 2021) and substantive authorisation for a period of 12 months from the date of the final determination.

On 29 September 2021, the ACCC granted interim authorisation with a condition.

On 11 November 2021, the ACCC issued a draft determination proposing to grant re-authorisation until 30 September 2022 with a condition.

On 8 December 2021, the ACCC issued a final determination granting re-authorisation with a condition to Medicines Australia to engage in the Conduct for the sole purpose of ensuring the supply of essential medicines and related devices in response to issues arising from the COVID-19 pandemic. Re-authorisation is granted until 30 September 2022.

Further information is available below.


  • Medicines Australia

Authorisation number(s)

  • AA1000579-1


Document title Date
Application Received

ACCC correspondence

Submissions - before draft decision